Summary of the main contents of the Chinese manual of Epclusa

Epclusa is an oral antiviral compound preparation developed by Gilead Sciences for the treatment of hepatitis C virus (HCV) infection. The Chinese instructions cover the drug ingredients, indications, usage and dosage, adverse reactions, precautions, etc. The following is a detailed summary of the Chinese instructions for Jisandai to help patients better understand the use and precautions of this drug.

First of all, from the perspective of drug ingredients, Jisandai is a fixed-dose compound preparation, and each tablet contains sofosbuvir (Sofosbuvir)40 0mgand Velpatasvir (Velpatasvir)100mg. Both ingredients are direct-acting antiviral drugs (DAAs) that target and inhibit key enzymes required for HCV replication. Sofosbuvir is an NS5B polymerase inhibitor, while velpatasvir is an NS5A NS5A inhibitor. The two combine to act on different stages of virus replication, thereby achieving a broader and more efficient antiviral effect, and are active against 6 types of HCV genotypes.

In terms of indications, Jisandai is suitable for adults and adolescent patients 12 years old and above to treat chronic infections of hepatitis C of all genotypes (1 to 6 types), including patients with compensated cirrhosis or decompensated cirrhosis. In the presence of cirrhosis or other health problems (such as HIV co-infection), Jisandai still shows good efficacy. For patients with decompensated cirrhosis, Gisanda can be used in combination with ribavirin to enhance the therapeutic effect. Its broad spectrum makes it one of the most important choices in the current clinical treatment of hepatitis C.

Regarding usage and dosage, the recommended dosage of Jisandai is one tablet once a day, which can be taken before or after meals. The course of treatment is generally 12 weeks, and the specific duration depends on the patient's liver condition, whether it is combined with other diseases, and previous treatment history. For patients with decompensated cirrhosis or some special groups, doctors may add ribavirin to the third generation of gynecology for combined treatment. During the treatment period, you should insist on taking the medicine regularly every day. You should not stop taking the medicine, reduce the dosage or miss a dose without authorization. If you miss a dose, you should take it as soon as possible and do not take it again within the next 24 hours.

The instructions also detail possible adverse reactions. Most patients tolerate Jisandai well, but a small number of people may experience minor discomforts such as headache, fatigue, nausea, insomnia, loss of appetite, etc. These are usually short-term, reversible reactions. In some cases, serious symptoms such as rash, depression, and difficulty breathing may occur, which require attention. For patients treated with ribavirin, they need to be wary of side effects such as anemia, dry skin, and fatigue. The instructions suggest that liver function, viral load and blood indicators should be monitored regularly during treatment in order to adjust the treatment plan in a timely manner.

在注意事项方面，吉三代禁止与某些药物联用，如利福平、圣约翰草、卡马西平等，这些药物可能影响吉三代在体内的药物浓度，从而降低治疗效果。 Pregnant women, lactating women, and patients with severely impaired kidney function should use it with caution under the guidance of a doctor. Report all medications, supplements, or herbal medicines you are taking to your doctor before taking them to avoid unnecessary drug interactions.

Overall, Jisandai is a highly effective, broad-spectrum, and safe hepatitis C treatment drug. Its advantages of taking one tablet a day and a short course of treatment significantly reduce patients' compliance pressure and improve the cure rate. By understanding the main contents of the Chinese instructions, patients can more clearly grasp the regulatory requirements and precautions for drug use, thereby achieving safer and more effective antiviral treatment goals. With the promotion of this drug in China, it is expected to continue to benefit the majority of hepatitis C patients.

Reference: https://www.epclusa.com/